BR112014028944A2 - vetores lentivirais contendo um promotor de mhc classe i - Google Patents

vetores lentivirais contendo um promotor de mhc classe i

Info

Publication number
BR112014028944A2
BR112014028944A2 BR112014028944A BR112014028944A BR112014028944A2 BR 112014028944 A2 BR112014028944 A2 BR 112014028944A2 BR 112014028944 A BR112014028944 A BR 112014028944A BR 112014028944 A BR112014028944 A BR 112014028944A BR 112014028944 A2 BR112014028944 A2 BR 112014028944A2
Authority
BR
Brazil
Prior art keywords
class
vectors containing
lentiviral vectors
promoter
vectors
Prior art date
Application number
BR112014028944A
Other languages
English (en)
Other versions
BR112014028944B1 (pt
Inventor
Cecile Bauche
Emeline Sarry
Original Assignee
Theravectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys filed Critical Theravectys
Publication of BR112014028944A2 publication Critical patent/BR112014028944A2/pt
Publication of BR112014028944B1 publication Critical patent/BR112014028944B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo da patente de invenção para: “vetores lentivirais contendo um promotor de mhc classe i”. a presente invenção refere-se à inserção de uma sequência promotora de um promotor do gene de mhc classe i em um vetor lentiviral, de forma a direcionar a transcrição de um transgene, que preferivelmente codifica um polipeptídeo imunogênico para ser expresso em um hospedeiro de células de mamífero, preferivelmente apc (dcs). a invenção abrange estes vetores, métodos para produzir os vetores e métodos de utilização destes, incluindo utilizações medicinais.
BR112014028944-1A 2010-05-23 2013-04-30 vetores lentivirais contendo um promotor de mhc classe i BR112014028944B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305566.7A EP2666477A1 (en) 2012-05-23 2012-05-23 Lentiviral vectors containing an MHC class I promoter
EP12305566.7 2012-05-23
PCT/EP2013/059041 WO2013174630A1 (en) 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter

Publications (2)

Publication Number Publication Date
BR112014028944A2 true BR112014028944A2 (pt) 2015-09-29
BR112014028944B1 BR112014028944B1 (pt) 2020-11-10

Family

ID=48289150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028944-1A BR112014028944B1 (pt) 2010-05-23 2013-04-30 vetores lentivirais contendo um promotor de mhc classe i

Country Status (18)

Country Link
US (1) US8951535B2 (pt)
EP (2) EP2666477A1 (pt)
JP (1) JP5938143B2 (pt)
KR (1) KR101774929B1 (pt)
CN (1) CN104736167B (pt)
AU (1) AU2013265586B2 (pt)
BR (1) BR112014028944B1 (pt)
CA (1) CA2873473C (pt)
ES (1) ES2498277T3 (pt)
HK (1) HK1211837A1 (pt)
IL (1) IL235705A (pt)
IN (1) IN2014DN10123A (pt)
NZ (1) NZ702345A (pt)
PL (1) PL2678032T3 (pt)
PT (1) PT2678032E (pt)
SG (1) SG11201407732SA (pt)
WO (1) WO2013174630A1 (pt)
ZA (1) ZA201408652B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509743WA (en) * 2013-06-03 2015-12-30 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
KR20220005208A (ko) 2020-07-06 2022-01-13 주식회사 지씨셀 면역원성이 감소된 신규한 이식용 세포
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720152A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Retrovirales Vektorsystem zur Optimierung des Gentransfers und der Genexpression in primären humanen T-Lymphozyten
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DK2169073T3 (da) * 1999-10-11 2014-02-10 Pasteur Institut Vektor til fremstilling af immunterapeutiske præparater
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CN108114276A (zh) 2007-08-03 2018-06-05 巴斯德研究院 慢病毒基因转移载体及其医学应用

Also Published As

Publication number Publication date
NZ702345A (en) 2016-03-31
AU2013265586A1 (en) 2014-12-11
EP2678032A1 (en) 2014-01-01
HK1211837A1 (en) 2016-06-03
JP5938143B2 (ja) 2016-06-22
KR101774929B1 (ko) 2017-09-19
KR20150014472A (ko) 2015-02-06
PT2678032E (pt) 2014-09-09
EP2666477A1 (en) 2013-11-27
PL2678032T3 (pl) 2014-11-28
US8951535B2 (en) 2015-02-10
JP2015518716A (ja) 2015-07-06
AU2013265586B2 (en) 2015-09-03
IN2014DN10123A (pt) 2015-08-21
CN104736167A (zh) 2015-06-24
CN104736167B (zh) 2018-07-27
CA2873473C (en) 2019-05-07
CA2873473A1 (en) 2013-11-28
EP2678032B1 (en) 2014-06-18
US20140120132A1 (en) 2014-05-01
SG11201407732SA (en) 2014-12-30
ZA201408652B (en) 2016-09-28
ES2498277T3 (es) 2014-09-24
IL235705A0 (en) 2015-01-29
BR112014028944B1 (pt) 2020-11-10
IL235705A (en) 2016-10-31
WO2013174630A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
BR112014018396A8 (pt) Imunógenos para vacinação contra hiv
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2013012596A (es) Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
NZ708144A (en) Recombinant adenoviruses and use thereof
CO7170149A2 (es) Producción mejorada de derivados de ácidos grasos
BR112018012694A2 (pt) composição de célula dendrítica, vacina de célula dendrítica, composição e kit
BR112014028944A2 (pt) vetores lentivirais contendo um promotor de mhc classe i
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112014019901A8 (pt) Proteínas de fator viii recombinante
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
CR20190431A (es) Formatos mejorados de receptor de unión a antígeno
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP4253534A3 (en) Alpha-amylase variants and polynucleotides encoding same
BR112014026206A2 (pt) sistemas e métodos celulares para melhorar a síntese de ácidos graxos através da expressão da desidrogenase
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
EA201290813A1 (ru) Полиэпитопные конструкции и способы их получения и применения
AU2015247777A8 (en) Codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR)
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
EP3998341A3 (en) Adenoviral vectors

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2013, OBSERVADAS AS CONDICOES LEGAIS.